Aurora (TSX:ACB) Stock: Restructuring, Layoffs, and More

Can Aurora Cannabis (TSX:ACB)(NYSE:ACB) stock make a comeback after its focus on restructuring?

| More on:
edit Cannabis leaves of a plant on a dark background

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s premium investing services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn moresdf

On June 23, 2020, leading marijuana producer Aurora Cannabis (TSX:ACB)(NYSE:ACB) provided an update with respect to its business transformation plan. Aurora Cannabis executed a material reduction in its corporate- and production-level employees as well as third-party consulting and professional spending.

This includes a 25% reduction in the company’s selling, general, and administrative (SG&A) staff and a 30% reduction in production staff. While the SG&A layoff will be with immediate effect, production staff capacity will move lower over the next two quarters.

Aurora Cannabis has forecast its fiscal first quarter of 2021 SG&A run-rate at $42 million. In the March quarter, the company’s SG&A expenses stood at $75.1 million. Aurora Cannabis is confident about generating higher levels of revenue in the upcoming quarters without a corresponding level of growth in SG&A expenses.

Aurora stock moved 10% higher in early market trading yesterday on this news. However, these gains were wiped out, and Aurora stock ended the day at a loss of 0.8%.

Aurora Cannabis will focus production at manufacturing facilities

Aurora plans to close operations at five facilities over the next two quarters and focus production and manufacturing at its larger scale and higher efficient facilities. It announced sites at Aurora Prairie, Aurora Mountain, Aurora Ridge, Aurora Vie, and Aurora Eau will close.

Aurora expects to consolidate Canadian production and manufacturing at Aurora Sky, Aurora River, Polaris, and Whistler Pemberton facilities by the end of the September quarter. The company is also looking to ramp up production at its Nordic facility in Europe to keep up with demand in these markets.

Aurora estimates asset impairment charges of up to $60 million in the fourth quarter of 2020. It will also record a $140 million charge in the carrying value of inventory. Aurora Cannabis is optimistic about the company’s focus on maintaining production efficiencies and yield improvements.

It expects the facility closures to be accretive to gross margins, as the shift towards large production facilities will result in economies of scale. Aurora forecasts a material reduction in per-unit cost of goods by the third fiscal of 2021.

Aurora Cannabis CEO Michael Singer stated, “With today’s announcement we have achieved our stated SG&A run-rate target and expect to operate at approximately $42 million for the first quarter of fiscal 2021 … This has not simply been a cost cutting exercise. We have undertaken a strategic realignment of our operations to protect Aurora’s position as a leader in key global cannabinoid markets, most notably Canada.”

Will Aurora stock move higher in 2020?

Aurora stock has returned 145% since it reported fiscal Q3 2020 results in May. Its revenue was up 35% sequentially at $75.5 million in Q3 while its cash balance rose to $230.2 million. The company had then reaffirmed its target of achieving positive EBITDA in the first quarter of fiscal 2021.

Aurora Cannabis used $154.6 million in cash in Q3. Though its cash requirement fell by 43%, the company’s liquidity will make investors nervous. It raised equity capital several times in the last year, which diluted investor wealth. The company’s board of directors recently authorized a US$350 million at-the-market offering.

Aurora is confident its facility rationalization and inventory revaluation will improve gross margins and accelerate its ability to generate positive cash flow. If Aurora Cannabis can manage to lower costs and generate a positive EBITDA without a drastic fall in revenue, its stock can stage a comeback in 2020.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Aditya Raghunath has no position in any of the stocks mentioned.

More on Cannabis Stocks

Cannabis smoke
Cannabis Stocks

Canopy Growth Stock: Is Now a Good Time to Invest?

The road ahead is highly uncertain for Canopy Growth, as the stock is plagued with losses and seemingly unsurmountable industry…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

TLRY Stock: Should You Invest Now?

TLRY is a Canadian cannabis stock which is trading 91% below record highs. Let's see if you should own TLRY…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

Is Tilray Stock a Buy in February 2023?

Despite the volatile cannabis sector, Tilray could be a superb buy for long-term investors.

Read more »

Young woman sat at laptop by a window
Cannabis Stocks

Is SNDL Stock a Buy in February 2023?

SNDL is a beaten-down cannabis stock. While its revenue growth is exceptional, a weak balance sheet has driven stock prices…

Read more »

A cannabis plant grows.
Cannabis Stocks

TLRY Stock: Here’s What’s Coming in 2023

Tilray Inc. (TSX:TLRY) is geared up for big growth this decade and looks like one of the top cannabis stocks…

Read more »

A person holds a small glass jar of marijuana.
Cannabis Stocks

Canopy Growth Stock: Here’s What’s Coming in 2023

Canopy Growth stock has made a lot of new moves in the last few months, but where is the company…

Read more »

A cannabis plant grows.
Cannabis Stocks

Better Cannabis Buy: Canopy Growth Stock or Tilray?

Only two TSX weed stocks can deliver substantial returns in the highly anticipated growth of the global cannabis market.

Read more »

Medicinal research is conducted on cannabis.
Cannabis Stocks

Is Tilray Stock a Buy in January 2023?

Tilray stock has lost 50% of its value in the last 12 months, in line with its peers.

Read more »